Long noncoding RNA DRAIC acts as a microRNA-122 sponge to facilitate nasopharyngeal carcinoma cell proliferation, migration and invasion via regulating SATB1

Liao, Bing; Wang, Zhi; Zhu, Yaqiong; Wang, Meiqun; Liu, Yuehui

doi:10.1080/21691401.2019.1656638

Cited by 22 publications

(13 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering that the role of this lncRNA has not been investigated in colon cancer before this study, further experiments are essential to validate the effect of ZNF503-AS1 on colon cancer prognosis. DRAIC could inhibit the progression of prostate cancer ( Saha et al, 2020 ) and gastric cancer ( Zhang Z. et al, 2020 ), facilitate the proliferation and migration of nasopharyngeal carcinoma ( Liao et al, 2019 ) and regulate autophagic flux ( Tiessen et al, 2019 ). PTPRD-AS1 had potential as a prognostic predictor and was included in an immunotherapeutic response lncRNA signature for bladder cancer ( Gao X. et al, 2019 ; Wu et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Identification of a Genome Instability-Associated LncRNA Signature for Prognosis Prediction in Colon Cancer

2021

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) were reported to have the potential in maintaining genome instability, but the identification of lncRNAs related to genome instability and their prognostic value have not been largely explored in colon cancer. In this study, we obtained 155 genome instability-associated lncRNAs based on somatic mutation profiles in colon cancer from The Cancer Genome Atlas (TCGA) database. Functional enrichment analysis revealed the possible roles of genes co-expressed with those lncRNAs involved in some cancer, genome instability and immune related biological processes. Combined with overall survival data, a seven-lncRNA signature was established for prognosis prediction. According to the risk score calculated by this signature, high-risk patients characterized by high somatic mutation count, high microsatellite instability, significantly poorer clinical outcomes and specific tumor immune infiltration status compared with low-risk patients. The lncRNA signature was validated to be an independent prognostic indicator with good predictive performance in TCGA cohort. Furthermore, the prognostic value of the ZNF503-AS1 in lncRNA signature was confirmed in another independent dataset from Gene Expression Omnibus database. In summary, the genome instability-associated lncRNA signature in this study could be a promising tool for effectively predicting survival outcomes in colon cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of a Genome Instability-Associated LncRNA Signature for Prognosis Prediction in Colon Cancer

2021

View full text Add to dashboard Cite

show abstract

“…Based on the differential expression of DRAIC in GC and NC tissues and its potential role in several malignant tumors [10][11][12][13][14][15][16][17], we decided to explore the relationship between DRAIC/ NFRKB and malignant phenotype of GC cells. It was found that DRAIC can restrain the proliferation abilities of HGC-27 and MKN45 cells ( Fig.…”

Section: Biological Effects Of Oedraic and Rescued By Oenfrkb On Gc Cmentioning

confidence: 99%

“…The lncRNA DRAIC gene, which is located on human chromosome 15q23, was reported as a novel tumor regulator in several cancers recently, but it seemed to exhibit different biological effects in cancer cells from different sources [10][11][12][13][14][15][16][17]. On account of the potential value of DRAIC as a GC marker and target, we intended to reveal the expression characteristics and precise mechanism of DRAIC.…”

Section: Biological Effects Of Shdraic On Gc Cellsmentioning

confidence: 99%

“…Although the anti-cancer effects of DRAIC have been verified by some studies, there were still several sources of evidence that DRAIC also plays an oncogenic role in other cancers such as breast cancer (BC) and nasopharyngeal carcinoma (NPC). Research showed that DRAIC was highly expressed in BC and NPC, and was positively correlated with pathological stage, lymph node metastasis and poor prognosis of patients [14][15][16]. Simultaneously, DRAIC could facilitate proliferation of BC independently of autophagy [14] and enhance the malignant phenotype of NPC via adsorbing microRNA-122 and up-regulating special AT rich sequence-binding protein-1 (SATB1).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

LncRNA DRAIC inhibits proliferation and metastasis of gastric cancer cells through interfering with NFRKB deubiquitination mediated by UCHL5

Zhang

Kuang

et al. 2020

Cell Mol Biol Lett

View full text Add to dashboard Cite

Background: Long non-coding RNA (lncRNA) as a widespread and pivotal epigenetic molecule participates in the occurrence and progression of malignant tumors. DRAIC, a kind of lncRNA whose coding gene location is on 15q23 chromatin, has been found to be weakly expressed in a variety of malignant tumors and acts as a suppressor, but its characteristics and role in gastric cancer (GC) remain to be elucidated. Methods: Sixty-seven primary GC tissues and paired paracancerous normal tissues were collected. Bioinformatics is used to predict the interaction molecules of DRAIC. DRAIC and NFRKB were overexpressed or interfered exogenously in GC cells by lentivirus or transient transfection. Quantitative real-time PCR (qPCR) and western blotting were used to evaluate the expression of DRAIC, UCHL5 and NFRKB. The combinations of DRAIC and NFRKB or UCHL5 and NFRKB were verified by RNA-IP and Co-IP assays. Ubiquitination-IP and the treatment of MG132 and CHX were used to detect the ubiquitylation level of NFRKB. The CCK-8 and transwell invasion and migration assays measured the proliferation, migration and invasion of GC cells. Results: DRAIC is down-regulated in GC tissues and cell lines while its potential interacting molecules UCHL5 and NFRKB are up-regulated, and DRAIC is positively correlated with NFRKB protein instead of mRNA. Lower DRAIC and higher UCHL5 and NFRKB indicated advanced progression of GC patients. DRAIC could increase NFRKB protein significantly instead of NFRKB mRNA and UCHL5, and bind to UCHL5. DRAIC combined with UCHL5 and attenuated binding of UCHL5 and NFRKB, meanwhile promoting the degradation of NFRKB via ubiquitination, and then inhibited the proliferation and metastasis of GC cells, which can be rescued by oeNFRKB. Conclusion: DRAIC suppresses GC proliferation and metastasis via interfering with the combination of UCHL5 and NFRKB and mediating ubiquitination degradation.

show abstract

“…Other known oncogenic lncRNAs involved in NPC include HOTTIP, HOTAIR, ROR, XIST, HNF1A-AS, DRAIC, NPCCAT1, ANRIL, H19, LINC01385, LINC01503, CASC15, PXN-AS1-L, LINC00460, and UCA1, which involve in increasing cell proliferation, migration, invasion, and metastasis [106][107][108][109][110][111][112][113][114][115][116][117][118][119][120]. High expressions of LINC00319, LINC01503, HOTTIP, PXN-AS1-L, ANRIL, HOTAIR, LINC01385, and XIST are associated with poor prognosis and short overall survival in NPC [106,107,109,113,115,117,120,121].…”

Section: Long Noncoding Rnas (Lncrnas) In Npcmentioning

confidence: 99%

Diagnostic and Prognostic Indications of Nasopharyngeal Carcinoma

Irekeola

Yean

2020

Diagnostics

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is a disease that is highly associated with the latent infection of Epstein–Barr virus. The absence of obvious clinical signs at the early stage of the disease has made early diagnosis practically impossible, thereby promoting the establishment and progression of the disease. To enhance the stride for a reliable and less invasive tool for the diagnosis and prognosis of NPC, we synopsize biomarkers belonging to the two most implicated biological domains (oncogenes and tumor suppressors) in NPC disease. Since no single biomarker is sufficient for diagnosis and prognosis, coupled with the fact that the known established methods such as methylation-specific polymerase chain reaction (PCR), multiplex methylation-specific PCR, microarray assays, etc., can only accommodate a few biomarkers, we propose a 10-biomarker panel (KIT, LMP1, PIKC3A, miR-141, and miR-18a/b (oncogenic) and p16, RASSF1A, DAP-kinase, miR-9, and miR-26a (tumor suppressors)) based on their diagnostic and prognostic values. This marker set could be explored in a multilevel or single unified assay for the diagnosis and prognosis of NPC. If carefully harnessed and standardized, it is hoped that the proposed marker set would help transform the diagnostic and prognostic realm of NPC, and ultimately, help prevent the life-threatening late-stage NPC disease.

show abstract

Long noncoding RNA DRAIC acts as a microRNA-122 sponge to facilitate nasopharyngeal carcinoma cell proliferation, migration and invasion via regulating SATB1

Cited by 22 publications

References 58 publications

Identification of a Genome Instability-Associated LncRNA Signature for Prognosis Prediction in Colon Cancer

Identification of a Genome Instability-Associated LncRNA Signature for Prognosis Prediction in Colon Cancer

LncRNA DRAIC inhibits proliferation and metastasis of gastric cancer cells through interfering with NFRKB deubiquitination mediated by UCHL5

Diagnostic and Prognostic Indications of Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About